Momenta Pharmaceuticals Inc. announced unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2017. For the quarter, the company reported total collaboration revenue of $64,608,000 compared to $34,195,000 a year ago. Income from operations was $12,633,000 compared to loss of $10,352,000 a year ago. Net income was $13,759,000 or $0.18 per basic and diluted share compared to $41,539,000 or $0.60 per basic and diluted share a year ago.

For the year, the company reported total collaboration revenue of $138,882,000 compared to $109,619,000 a year ago. Loss from operations was $92,551,000 compared to $74,727,000 a year ago. Net loss was $88,096,000 or $1.20 per basic and diluted share compared to $21,003,000 or $0.31 per basic and diluted share a year ago.

The company provided revenue guidance for the first quarter of 2018. The company estimates that collaborative reimbursement revenues will be approximately $0 to $2 million per quarter in 2018.